In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of gram-negative bacilli

Chemotherapy

Volumn 49, Issue 1-2, 2003, Pages 44-48

  Critchley, Ian A ^a   Sahm, Daniel F ^a   Kelly, Laurie J ^a   Karlowsky, James A ^a  

^a Focus Technologies Incorporated   (United States)

Author keywords

Aztreonam; Fluoroquinolones; Gram negative pathogens; Synergy testing

Indexed keywords

AZTREONAM; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; AZTREONAM; BURKHOLDERIA CEPACIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FLUOROQUINOLONES; GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SPECIES SPECIFICITY;

EID: 0037262682     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069786     Document Type: Article

References (22)

1. Braunwald E, Jameson JL, Longo DL (eds): Harrison's Principles of Internal Medicine, ed 15. New York, McGraw-Hill, 2001.
2. Eliopoulos GM, Moellering RC Jr: Antimicrobial combinations; in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 4. Baltimore, Williams & Wilkins, 1996, pp 330-338.
3. Rittenbury MS: How and why aztreonam works. Surg Gynecol Obstet 1990;171(suppl):19-23.
4. Pfaller MA, Jones RN, Doern GV, Kugler K: Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998;42:1762-1770.
5. The Surveillance Network® Database-USA (data on file). Herndon, Focus Technologies, 2001.
6. Buesing MA, Jorgensen JH: In vitro activity of aztreonam in combination with the newer β-lactams and amikacin against multiply resistant gram-negative bacilli. Antimicrob Agents Chemother 1984;25:283-285.
7. Chang SC, Chen YC, Luh KT, Hsieh WC: In vitro activities of antimicrobial agents alone and in combination against Acinetobacter baumannii isolated from blood. Diagn Microbiol Infect Dis 1995;23:105-110.
8. Gerceker AA, Gurler B: In-vitro activities of antibiotics alone and in combination with amikacin against Pseudomonas aeruginosa. J Antimicrob Chemother 1995;36:707-711.
9. Schaad UB, Wedgwood-Krucko J, Guenin K, Buehlmann U, Kraemer R: Antipseudomonal therapy for cystic fibrosis: Aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis 1989;8:858-865.
10. Bosso JA, Saxon BA, Matsen JM: In vitro activities of combinations of aztreonam, ciprofloxacin and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Antimicrob Agents Chemother 1990;34:487-488.
11. Bustamante CI, Wharton RC, Wade JC: In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990;34:1814-1815.
12. Pohlman JK, Knapp CC, Ludwig MD, Washington JA: Timed killing kinetic studies of the interaction between ciprofloxacin and β-lactams against Gram-negative bacilli. Diagn Microbiol Infect Dis 1996;26:29-33.
13. Flynn CM, Johnson DM, Jones RN: In vitro efficacy of levofloxacin alone, or in combination tested against multi-resistant Pseudomonas aeruginosa strains. J Chemother 1996;8: 411-415.
14. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing; 11th informational supplement M100-S11. Wayne, NCCLS, 2001.
15. Scribner RK, Marks MI, Weber AH, Tarpay MM, Welch DF: Activities of various β-lac-tams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrob Agents Chemother 1982;21:939-943.
16. Hallander HO, Dornbusch K, Gezelius L, Jacobson K, Karlsson I: Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: Interaction index and killing curve method. Antimicrob Agents Chemother 1982;22:743-752.
17. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, ed 5. Approved standard M7-A5. Wayne, NCCLS, 1997.
18. Waterer GW, Wunderink RG: Increasing threat of Gram-negative bacteria. Crit Care Med 2001;29(4 suppl):N75-N81.
19. Sahm DF, Critchley IA, Kelly LJ, Karlowsky JA, Mayfield DC, Thornsberry C, Mauriz Y, Kahn J: Evaluation of current activities of fluoroquinolones against Gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob Agents Chemother 2000;45:267-274.
20. Rand KH, Houck HJ, Brown P, Bennett D: Reproducibility of the microdilution checker-board method for antibiotic synergy. Antimicrob Agents Chemother 1993;37:613-615.
21. Hsieh MH, Yu CM, Yu VL, Chow JW: Synergy assessed by checkerboard. A critical analysis. Diagn Microbiol Infect Dis 1993;16:343-349.
22. Mackay ML, Milne K, Gould IM: Comparison of methods for assessing synergic antibiotic interactions. Int J Antimicrob Agents 2000;15:125-129.